AAAAAA

   
Results: 1-18 |
Results: 18
Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life
Authors: Bethoux, F Miller, DM Kinkel, RP
Citation: F. Bethoux et al., Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life, MULT SCLER, 7(2), 2001, pp. 137-142
Interferon beta-1a during a first demyelinating event. Reply
Authors: Jacobs, JD Beck, RW Kinkel, RP
Citation: Jd. Jacobs et al., Interferon beta-1a during a first demyelinating event. Reply, N ENG J MED, 344(3), 2001, pp. 229-230
Axonal loss in normal-appearing white matter in a patient with acute MS
Authors: Bjartmar, C Kinkel, RP Kidd, G Rudick, RA Trapp, BD
Citation: C. Bjartmar et al., Axonal loss in normal-appearing white matter in a patient with acute MS, NEUROLOGY, 57(7), 2001, pp. 1248-1252
Transcallosal bands: A sign of neuronal tract degeneration in early MS?
Authors: Simon, JH Jacobs, L Kinkel, RP
Citation: Jh. Simon et al., Transcallosal bands: A sign of neuronal tract degeneration in early MS?, NEUROLOGY, 57(10), 2001, pp. 1888-1890
Interferon beta-1 a for optic neuritis patients at high risk for multiple sclerosis
Authors: O'Connor, P Fleming, P Gray, T Jacobs, L Miller, C Munschauer, F Kinkel, RP Bolibrush, D Cohen, J Freedman, M Webb, U Rabinowicz, H Metz, LM Patry, D Yeung, M Peters, S Hashimoto, S Morrison, W Oger, J Panitch, H Costello, K Bever, C Stuart, W Court, D Stuart, D Tornatore, C Bartlett, D Richert, J Duquette, P Dubois, R Bernier, G Scott, T Pappert, L Brillman, J Felton, W Anderson, T Astruc, J Rose, J Kline, J Burns, J Murray, T Weldon, P Bhan, V Maxner, CE Wall, M Vining, L Grabowski, T Apatoff, B Arapello, K Friedman, J Galetta, S Pfohl, D Liu, G Rice, G Bental, T Mandalfino, P Eggenberger, E Snider, D Kaufman, D Guarnaccia, J Shepard, M Goldstein, J Reiss, M Carter, E Glista, G Rolak, L Scheller, L Jacobson, D Warner, J Goodman, A Petrie, M Mattson, D Karlin, K Wallin, A Stefoski, D Brod, S Cerretta, E Wolinsky, J Arnold, D Arnoutelis, R Durcan, L Kupersmith, M Cappolino, L Herbert, J Rosenberg, J McHugh, D Blumenfeld, A Smith, C Kuder, D Hamilton, S Thurston, S McGee, J O'Bannon, J Kaufman, M Butler, M Putnam, S Rammohan, K Siffort, A Lynn, J Selhorst, J Holzemer, E Hayat, G Tselis, A Coon, C Lisak, R Wray, S Sexton, P Lehrich, J Cook, S Jotkowitz, A Bansil, S Newman, N Brown, J Pennell, P Gilmore, J Carter, J Buckner, J Caselli, R Kerson, L Camasso, M Donneief, G Cooper, J Richardson, B Kung, C Goodwin, J Johnson, T Gulati, A Hedges, T Yardley, C Tran, T Brown, W Ehrenberg, B Horowitz, S Bonnett, A Burger, R Javerbaum, J Griffin, C Whaley, RJ Jeffery, D Jackson, SE Bastings, E Kasper, L Ryan, K Bernat, J Mass, M Hanel, SC Bourdette, D Guy, J Wilson, M Greer, M Lucchinetti, C Botten, M Noseworthy, J Walker, A Muntz, B Tyor, W Simon, J Meyer, M Leek, R Gustafson, C Singel, D Quandt, B Miller, DE Coombs, B Cajade-Law, A Lajaunie, M Escott, E Miller, A Richert, J Cohen, J Vollmer, T Oger, J Jacobs, L Beck, R Kinkel, RP Brownscheidle, C Murray, TJ Simon, J Antel, J Myers, L Birnbaum, G Reingold, S Burde, R Sibley, W Ware, J Blanchard, N Lloyd, K Park, H Sandrock, A Simonian, N Slasor, P Votruba, F White, K Beck, R Chandler, DL Cole, S Felton, W Galetta, S Jacobs, L Kinkel, RP Kupersmith, M Murray, TJ Newman, N Sandrock, A Simon, J Simonian, N
Citation: P. O'Connor et al., Interferon beta-1 a for optic neuritis patients at high risk for multiple sclerosis, AM J OPHTH, 132(4), 2001, pp. 463-471
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
Authors: Jacobs, LD Beck, RW Simon, JH Kinkel, RP Brownscheidle, CM Murray, TJ Simonian, NA Slasor, PJ Sandrock, AW
Citation: Ld. Jacobs et al., Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis., N ENG J MED, 343(13), 2000, pp. 898-904
A longitudinal study of T1 hypointense lesions in relapsing MS - MSCRG trial of interferon beta-1a
Authors: Simon, JH Lull, J Jacobs, LD Rudick, RA Cookfair, DL Herndon, RM Richert, JR Salazar, AM Sheeder, J Miller, D McCabe, K Serra, A Campion, MK Fischer, JS Goodkin, DE Simonian, N Lajaunie, M Wende, K Martens-Davidson, A Kinkel, RP Munschauer, FE
Citation: Jh. Simon et al., A longitudinal study of T1 hypointense lesions in relapsing MS - MSCRG trial of interferon beta-1a, NEUROLOGY, 55(2), 2000, pp. 185-192
A Wallerian degeneration pattern in patients at risk for MS
Authors: Simon, JH Kinkel, RP Jacobs, L Bub, L Simonian, N
Citation: Jh. Simon et al., A Wallerian degeneration pattern in patients at risk for MS, NEUROLOGY, 54(5), 2000, pp. 1155-1160
Traumatic intracerebral venous thrombosis associated with an abnormal golfswing
Authors: Saneto, RP Samples, S Kinkel, RP
Citation: Rp. Saneto et al., Traumatic intracerebral venous thrombosis associated with an abnormal golfswing, HEADACHE, 40(7), 2000, pp. 595-598
Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis'prevention' trials
Authors: Kinkel, RP Simon, JH Baron, B
Citation: Rp. Kinkel et al., Bimonthly cranial MRI activity following an isolated monosymptomatic demyelinating syndrome: potential outcome measures for future multiple sclerosis'prevention' trials, MULT SCLER, 5(5), 1999, pp. 307-312
Regression and spreading of self-recognition during the development of autoimmune demyelinating disease
Authors: Tuohy, VK Yu, M Yin, L Kawczak, JA Kinkel, RP
Citation: Vk. Tuohy et al., Regression and spreading of self-recognition during the development of autoimmune demyelinating disease, J AUTOIMMUN, 13(1), 1999, pp. 11-20
Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders
Authors: Cohen, JA Carter, JL Kinkel, RP Schwid, SR
Citation: Ja. Cohen et al., Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders, J NEUROIMM, 98(1), 1999, pp. 29-36
Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis
Authors: Rudick, RA Cookfair, DL Simonian, NA Ransohoff, RM Richert, JR Jacobs, LD Herndon, RM Salazar, AM Fischer, JS Granger, CV Goodkin, DE Simon, JH Bartoszak, DM Bourdette, DN Braiman, J Brownscheidle, CM Coats, ME Cohan, SL Dougherty, DS Kinkel, RP Mass, MK Munchsauer, FE O'Reilly, K Priore, RL Pullicino, PM Scherokman, BJ Wende, K Weinstock-Guttman, B Whitham, RH
Citation: Ra. Rudick et al., Cerebrospinal fluid abnormalities in a phase III trial of Avonex (R) (IFN beta-1a) for relapsing multiple sclerosis, J NEUROIMM, 93(1-2), 1999, pp. 8-14
Chronic thalamic stimulation for the tremor of multiple sclerosis
Authors: Montgomery, EB Baker, KB Kinkel, RP Barnett, G
Citation: Eb. Montgomery et al., Chronic thalamic stimulation for the tremor of multiple sclerosis, NEUROLOGY, 53(3), 1999, pp. 625-628
A longitudinal study of brain atrophy in relapsing multiple sclerosis
Authors: Simon, JH Jacobs, LD Campion, MK Rudick, RA Cookfair, DL Herndon, RM Richert, JR Salazar, AM Fischer, JS Goodkin, DE Simonian, N Lajaunie, M Miller, DE Wende, K Martens-Davidson, A Kinkel, RP Munschauer, FE Brownscheidle, CM
Citation: Jh. Simon et al., A longitudinal study of brain atrophy in relapsing multiple sclerosis, NEUROLOGY, 53(1), 1999, pp. 139-148
A phase II study of IV methylprednisolone in secondary progressive MS - Reply
Authors: Goodkin, DE Kinkel, RP
Citation: De. Goodkin et Rp. Kinkel, A phase II study of IV methylprednisolone in secondary progressive MS - Reply, NEUROLOGY, 52(4), 1999, pp. 896-897
Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis
Authors: Tuohy, VK Yu, M Yin, L Kawczak, JA Kinkel, RP
Citation: Vk. Tuohy et al., Spontaneous regression of primary autoreactivity during chronic progression of experimental autoimmune encephalomyelitis and multiple sclerosis, J EXP MED, 189(7), 1999, pp. 1033-1042
Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials
Authors: Goodkin, DE Priore, RL Wende, KE Campion, M Bourdette, DN Herndon, RM Fischer, JS Jacobs, LD Cookfair, DL Rudick, RA Richert, JR Salazar, AM Granger, CV Simon, JH Alam, JJ Bartoszak, DM Braiman, J Brownscheidle, CM Coats, ME Cohan, SL Dougherty, DS Kinkel, RP Mass, MK Munschauer, FE Pullicino, PM Scherokman, BJ Weinstock-Guttman, B Whitham, RH
Citation: De. Goodkin et al., Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials, MULT SCLER, 4(6), 1998, pp. 480-486
Risultati: 1-18 |